Loading...

Blonder Tongue Laboratories

AMEX:BDR
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BDR
AMEX
$9M
Market Cap
  1. Home
  2. US
  3. Tech
Company description

Blonder Tongue Laboratories, Inc., a technology-development and manufacturing company, provides television signal encoding, transcoding, digital transport, and broadband product solutions in the United States. The last earnings update was 64 days ago. More info.


Add to Portfolio Compare Print
BDR Share Price and Events
7 Day Returns
-1.9%
AMEX:BDR
0.5%
US Communications
-0.3%
US Market
1 Year Returns
-33.7%
AMEX:BDR
21.4%
US Communications
3.4%
US Market
BDR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Blonder Tongue Laboratories (BDR) -1.9% -2.9% 0.4% -33.7% 52% -1.9%
US Communications 0.5% 3.9% -1.9% 21.4% 71.8% 89.6%
US Market -0.3% 2.9% 2.1% 3.4% 36.2% 41.3%
1 Year Return vs Industry and Market
  • BDR underperformed the Communications industry which returned 21.4% over the past year.
  • BDR underperformed the Market in United States of America which returned 3.4% over the past year.
Price Volatility
BDR
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Blonder Tongue Laboratories undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Blonder Tongue Laboratories. This is due to cash flow or dividend data being unavailable. The share price is $0.942.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Blonder Tongue Laboratories's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Blonder Tongue Laboratories's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AMEX:BDR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.44
AMEX:BDR Share Price ** AMEX (2019-07-18) in USD $0.94
United States of America Communications Industry PE Ratio Median Figure of 35 Publicly-Listed Communications Companies 29.2x
United States of America Market PE Ratio Median Figure of 3,083 Publicly-Listed Companies 17.88x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Blonder Tongue Laboratories.

AMEX:BDR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:BDR Share Price ÷ EPS (both in USD)

= 0.94 ÷ 0.44

2.15x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Blonder Tongue Laboratories is good value based on earnings compared to the US Communications industry average.
  • Blonder Tongue Laboratories is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Blonder Tongue Laboratories's expected growth come at a high price?
Raw Data
AMEX:BDR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 2.15x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Communications Industry PEG Ratio Median Figure of 21 Publicly-Listed Communications Companies 1.34x
United States of America Market PEG Ratio Median Figure of 2,124 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Blonder Tongue Laboratories, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Blonder Tongue Laboratories's assets?
Raw Data
AMEX:BDR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $1.33
AMEX:BDR Share Price * AMEX (2019-07-18) in USD $0.94
United States of America Communications Industry PB Ratio Median Figure of 70 Publicly-Listed Communications Companies 1.87x
United States of America Market PB Ratio Median Figure of 5,245 Publicly-Listed Companies 1.8x
AMEX:BDR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:BDR Share Price ÷ Book Value per Share (both in USD)

= 0.94 ÷ 1.33

0.71x

* Primary Listing of Blonder Tongue Laboratories.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Blonder Tongue Laboratories is good value based on assets compared to the US Communications industry average.
X
Value checks
We assess Blonder Tongue Laboratories's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Communications industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Communications industry average (and greater than 0)? (1 check)
  5. Blonder Tongue Laboratories has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Blonder Tongue Laboratories expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Blonder Tongue Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.7%
Expected Communications industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Blonder Tongue Laboratories expected to grow at an attractive rate?
  • Unable to compare Blonder Tongue Laboratories's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Blonder Tongue Laboratories's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Blonder Tongue Laboratories's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
AMEX:BDR Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Communications Industry Earnings Growth Rate Market Cap Weighted Average 16.7%
United States of America Communications Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AMEX:BDR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AMEX:BDR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 20 -3 4
2018-12-31 22 1 -1
2018-09-30 22 0 0
2018-06-30 22 1 0
2018-03-31 23 0 0
2017-12-31 23 0 0
2017-09-30 23 0 -1
2017-06-30 23 1 -1
2017-03-31 23 1 -1
2016-12-31 23 1 -1
2016-09-30 22 0 -3
2016-06-30 23 1 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Blonder Tongue Laboratories is high growth as no earnings estimate data is available.
  • Unable to determine if Blonder Tongue Laboratories is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AMEX:BDR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Blonder Tongue Laboratories Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:BDR Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.44
2018-12-31 -0.15
2018-09-30 -0.04
2018-06-30 -0.04
2018-03-31 -0.02
2017-12-31 -0.05
2017-09-30 -0.12
2017-06-30 -0.18
2017-03-31 -0.15
2016-12-31 -0.16
2016-09-30 -0.42
2016-06-30 -0.64

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Blonder Tongue Laboratories will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Blonder Tongue Laboratories is trading at Blonder Tongue Laboratories'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Blonder Tongue Laboratories's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Tech companies here
  3. Blonder Tongue Laboratories's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Blonder Tongue Laboratories's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Blonder Tongue Laboratories has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Blonder Tongue Laboratories performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Blonder Tongue Laboratories's growth in the last year to its industry (Communications).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Blonder Tongue Laboratories has delivered over 20% year on year earnings growth in the past 5 years.
  • Blonder Tongue Laboratories has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Blonder Tongue Laboratories has become profitable in the last year making it difficult to compare the US Communications industry average.
Earnings and Revenue History
Blonder Tongue Laboratories's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Blonder Tongue Laboratories Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AMEX:BDR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 20.43 4.05 7.41 2.58
2018-12-31 21.71 -1.34 6.70 2.58
2018-09-30 21.84 -0.34 6.31 2.55
2018-06-30 21.79 -0.30 6.04 2.48
2018-03-31 22.67 -0.19 5.89 2.48
2017-12-31 23.28 -0.38 6.02 2.45
2017-09-30 23.16 -0.98 6.16 2.52
2017-06-30 23.02 -1.47 6.25 2.63
2017-03-31 22.54 -1.16 6.18 2.68
2016-12-31 22.51 -1.20 6.29 2.74
2016-09-30 22.27 -2.99 6.61 2.83
2016-06-30 22.54 -4.31 6.79 2.99
2016-03-31 22.14 -5.64 7.04 3.22
2015-12-31 20.94 -6.77 7.22 3.33
2015-09-30 21.79 -5.31 7.60 3.38
2015-06-30 24.75 -2.77 7.79 3.38
2015-03-31 28.29 -1.16 8.12 3.38
2014-12-31 29.13 -0.90 8.25 3.42
2014-09-30 30.25 -1.22 8.25 3.54
2014-06-30 28.41 -2.49 8.40 3.45
2014-03-31 26.73 -3.50 8.47 3.36
2013-12-31 27.87 -2.82 8.48 3.37
2013-09-30 28.41 -5.02 8.48 3.32
2013-06-30 30.20 -4.24 8.69 3.35
2013-03-31 30.85 -4.16 8.66 3.45
2012-12-31 30.64 -5.16 9.01 3.50
2012-09-30 29.38 -2.12 8.67 3.35

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Blonder Tongue Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Blonder Tongue Laboratories used its assets more efficiently than the US Communications industry average last year based on Return on Assets.
  • It is difficult to establish if Blonder Tongue Laboratories improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Blonder Tongue Laboratories's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Communications industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Blonder Tongue Laboratories has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Blonder Tongue Laboratories's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Blonder Tongue Laboratories's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Blonder Tongue Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Blonder Tongue Laboratories's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Blonder Tongue Laboratories's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 213x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Blonder Tongue Laboratories Company Filings, last reported 3 months ago.

AMEX:BDR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 12.78 0.05 1.63
2018-12-31 7.17 5.85 0.56
2018-09-30 7.68 5.95 0.10
2018-06-30 7.70 5.05 0.44
2018-03-31 7.43 6.06 0.24
2017-12-31 7.41 6.45 0.17
2017-09-30 6.59 6.44 0.20
2017-06-30 6.60 6.02 0.36
2017-03-31 6.76 6.14 0.54
2016-12-31 6.53 6.06 0.47
2016-09-30 6.89 5.77 0.21
2016-06-30 7.48 6.06 0.31
2016-03-31 7.13 6.73 0.51
2015-12-31 7.37 6.38 0.01
2015-09-30 9.26 6.23 0.30
2015-06-30 11.17 6.60 0.03
2015-03-31 12.38 5.52 0.09
2014-12-31 13.74 5.16 0.23
2014-09-30 15.00 4.96 1.43
2014-06-30 14.34 5.83 0.05
2014-03-31 13.93 5.34 0.11
2013-12-31 15.03 5.44 0.07
2013-09-30 15.00 5.42 0.05
2013-06-30 15.62 5.89 0.17
2013-03-31 16.21 6.12 0.08
2012-12-31 16.63 6.68 0.45
2012-09-30 19.42 7.98 0.17
  • Blonder Tongue Laboratories's level of debt (0.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (38.4% vs 0.4% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Blonder Tongue Laboratories's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Blonder Tongue Laboratories's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Blonder Tongue Laboratories has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Blonder Tongue Laboratories's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Blonder Tongue Laboratories dividends.
If you bought $2,000 of Blonder Tongue Laboratories shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Blonder Tongue Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Blonder Tongue Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AMEX:BDR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Communications Industry Average Dividend Yield Market Cap Weighted Average of 16 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Blonder Tongue Laboratories has not reported any payouts.
  • Unable to verify if Blonder Tongue Laboratories's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Blonder Tongue Laboratories's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Blonder Tongue Laboratories has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Blonder Tongue Laboratories's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Blonder Tongue Laboratories afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Blonder Tongue Laboratories has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Blonder Tongue Laboratories's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bob Pallé
COMPENSATION $170,090
AGE 73
TENURE AS CEO 4.2 years
CEO Bio

Mr. Robert J. Pallé, Jr., also known as Bob, has been Chief Executive Officer of Blonder Tongue Laboratories Inc since May 19, 2015. Mr. Pallé served as President at Blonder Tongue Laboratories, Inc. since May 5, 2003 until June 04, 2019. Mr. Pallé served as Blonder Tongue Laboratories Inc Chief Operating Officer and Secretary since April, 1989, Blonder Tongue Laboratories Inc Executive Vice President from April, 1989 until May, 2003 Mr. Pallé served as Interim Treasurer of Blonder Tongue Laboratories Inc. from March 2001 to April 2001. He has been a Director of Blonder Tongue Laboratories Inc., since September 1993.

CEO Compensation
  • Bob's compensation has increased in line with Blonder Tongue Laboratories recently becoming profitable.
  • Bob's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Blonder Tongue Laboratories management team in years:

4.2
Average Tenure
54
Average Age
  • The tenure for the Blonder Tongue Laboratories management team is about average.
Management Team

Bob Pallé

TITLE
CEO & Director
COMPENSATION
$170K
AGE
73
TENURE
4.2 yrs

Eric Skolnik

TITLE
Senior VP
COMPENSATION
$228K
AGE
54
TENURE
18.2 yrs

Ted Grauch

TITLE
President & COO
AGE
53
TENURE
0.1 yrs

Ron Alterio

TITLE
VP of Engineering & CTO
AGE
49
TENURE
1 yrs

Jeff Smith

TITLE
Vice President of Sales
COMPENSATION
$251K
AGE
55
TENURE
8.2 yrs
Board of Directors Tenure

Average tenure and age of the Blonder Tongue Laboratories board of directors in years:

9.6
Average Tenure
67
Average Age
  • The tenure for the Blonder Tongue Laboratories board of directors is about average.
Board of Directors

Steve Shea

TITLE
Chairman
COMPENSATION
$85K
AGE
60
TENURE
4.2 yrs

Bob Pallé

TITLE
CEO & Director
COMPENSATION
$170K
AGE
73
TENURE
25.8 yrs

Gary Scharmett

TITLE
Independent Director
COMPENSATION
$56K
AGE
63
TENURE
21.6 yrs

Anthony Bruno

TITLE
Independent Director
COMPENSATION
$60K
AGE
78
TENURE
11.4 yrs

Charles Dietz

TITLE
Independent Director
COMPENSATION
$59K
AGE
71
TENURE
7.8 yrs

James Williams

TITLE
Director
COMPENSATION
$55K
AGE
61
TENURE
25.8 yrs

James Williams

TITLE
Director
COMPENSATION
$52K
AGE
87
TENURE
4.4 yrs

Steve Necessary

TITLE
Director
COMPENSATION
$55K
AGE
62
TENURE
1.5 yrs
Who owns this company?
Recent Insider Trading
  • Blonder Tongue Laboratories individual insiders have sold more shares than they have bought in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
19. Jun 19 Sell James Williams Individual 17. Jun 19 18. Jun 19 -5,127 $0.99 $-5,026
12. Jun 19 Sell James Williams Individual 10. Jun 19 11. Jun 19 -10,000 $1.05 $-10,411
31. May 19 Buy Ronald Alterio Individual 28. May 19 28. May 19 5,000 $0.96 $4,801
29. May 19 Sell James Williams Individual 28. May 19 28. May 19 -5,000 $0.97 $-4,850
28. May 19 Sell James Williams Individual 23. May 19 23. May 19 -5,000 $0.95 $-4,750
21. May 19 Sell James Williams Individual 21. May 19 21. May 19 -5,000 $0.96 $-4,810
21. May 19 Sell James Williams Individual 20. May 19 20. May 19 -5,000 $0.92 $-4,600
20. Dec 18 Buy Edward Grauch Individual 14. Dec 18 14. Dec 18 637 $1.20 $764
19. Dec 18 Buy Edward Grauch Individual 17. Dec 18 17. Dec 18 9,261 $1.24 $11,484
19. Dec 18 Sell Jeffrey Smith Individual 17. Dec 18 17. Dec 18 -6,649 $1.14 $-7,553
18. Dec 18 Buy Ronald Alterio Individual 17. Dec 18 17. Dec 18 8,387 $1.25 $10,477
14. Dec 18 Buy Edward Grauch Individual 13. Dec 18 13. Dec 18 15,100 $1.20 $18,165
12. Dec 18 Buy Edward Grauch Individual 11. Dec 18 11. Dec 18 1,527 $1.14 $1,736
11. Dec 18 Buy Edward Grauch Individual 10. Dec 18 10. Dec 18 943 $1.15 $1,084
11. Dec 18 Buy Edward Grauch Individual 07. Dec 18 07. Dec 18 2,508 $1.15 $2,884
06. Dec 18 Sell Jeffrey Smith Individual 04. Dec 18 04. Dec 18 -31,666 $1.11 $-35,016
06. Dec 18 Buy Edward Grauch Individual 04. Dec 18 04. Dec 18 20,239 $1.14 $23,068
30. Nov 18 Buy Gary Scharmett Individual 30. Nov 18 30. Nov 18 10,000 $1.24 $12,400
30. Nov 18 Buy Gary Scharmett Individual 29. Nov 18 29. Nov 18 2,010 $1.17 $2,352
30. Nov 18 Buy Steven Shea Individual 28. Nov 18 28. Nov 18 30,000 $1.15 $34,584
30. Nov 18 Buy Edward Grauch Individual 27. Nov 18 27. Nov 18 2,217 $1.10 $2,439
28. Nov 18 Buy Edward Grauch Individual 26. Nov 18 26. Nov 18 27,568 $1.09 $30,093
X
Management checks
We assess Blonder Tongue Laboratories's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Blonder Tongue Laboratories has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Did Business Growth Power Blonder Tongue Laboratories's (NYSEMKT:BDR) Share Price Gain of 113%?

See our latest analysis for Blonder Tongue Laboratories While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. … AMEX:BDR Past and Future Earnings, July 12th 2019 We like that insiders have been buying shares in the last twelve months. … It is all well and good that insiders have been buying shares, but we suggest you check here to see what price insiders were buying at.

Simply Wall St -

Does The Blonder Tongue Laboratories, Inc. (NYSEMKT:BDR) Share Price Fall With The Market?

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … If this beta value holds true in the future, Blonder Tongue Laboratories shares are likely to rise more than the market when the market is going up, but fall faster when the market is going down. … What this means for you: Since Blonder Tongue Laboratories tends to moves up when the market is going up, and down when it's going down, potential investors may wish to reflect on the overall market, when considering the stock.

Simply Wall St -

How Much Of Blonder Tongue Laboratories, Inc. (NYSEMKT:BDR) Do Insiders Own?

The big shareholder groups in Blonder Tongue Laboratories, Inc. … Blonder Tongue Laboratories is a smaller company with a market capitalization of US$9.2m, so it may still be flying under the radar of many institutional investors. … Insider Ownership Of Blonder Tongue Laboratories While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

Investors Who Bought Blonder Tongue Laboratories (NYSEMKT:BDR) Shares Three Years Ago Are Now Up 189%

Blonder Tongue Laboratories isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … In the last 3 years Blonder Tongue Laboratories saw its revenue grow at 0.3% per year. … It may be that the market is pretty optimistic about Blonder Tongue Laboratories if you look to the bottom line

Simply Wall St -

How Should Investors React To Blonder Tongue Laboratories, Inc.'s (NYSEMKT:BDR) CEO Pay?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Bob Pallé's Compensation Compare With Similar Sized Companies. … has a market cap of US$11m, and is paying total annual CEO compensation of US$161k.

Simply Wall St -

What Percentage Of Blonder Tongue Laboratories, Inc. (NYSEMKT:BDR) Shares Do Insiders Own?

Every investor in Blonder Tongue Laboratories, Inc. … As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … Blonder Tongue Laboratories is not a large company by global standards.

Simply Wall St -

What Investors Should Know About Blonder Tongue Laboratories, Inc.'s (NYSEMKT:BDR) Financial Strength

(NYSEMKT:BDR) is a small-cap stock with a market capitalization of US$10m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

How Should Investors React To Blonder Tongue Laboratories Inc's (NYSEMKT:BDR) CEO Pay?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Bob Pallé's Compensation Compare With Similar Sized Companies. … Our data indicates that Blonder Tongue Laboratories Inc is worth US$9.7m, and total annual CEO compensation is US$161k.

Simply Wall St -

Is Blonder Tongue Laboratories Inc's (NYSEMKT:BDR) Balance Sheet A Threat To Its Future?

Investors are always looking for growth in small-cap stocks like Blonder Tongue Laboratories Inc (NYSEMKT:BDR), with a market cap of US$12.57m. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

Does Blonder Tongue Laboratories Inc's (NYSEMKT:BDR) Latest Financial Perfomance Look Strong?

Today I will take a look at Blonder Tongue Laboratories Inc's (NYSEMKT:BDR) most recent earnings update (31 March 2018) and compare these latest figures against its performance over the past few years, as well as how the rest of the communications industry performed. … See our latest analysis for Blonder Tongue Laboratories … BDR is loss-making, with the most recent trailing twelve-month earnings of -US$191.00k (from 31 March 2018), which compared to last year has become

Simply Wall St -

Company Info

Description

Blonder Tongue Laboratories, Inc., a technology-development and manufacturing company, provides television signal encoding, transcoding, digital transport, and broadband product solutions in the United States. It offers digital video headend products comprising high definition and SD, MPEG-2, and MPEG-4/H.264 encoders, as well as quadrature phase shift key to quadrature amplitude modulation (QAM) transcoders; digital QAM multiplexers; ATSC/QAM-IP transcoders; and EdgeQAM devices. The company provides its digital video headend products for use by system operators for acquisition, processing, compression, encoding, and management of digital videos. In addition, the company offers analog video headend products, including pre-fabricated headends to accommodate legacy analog television systems, modulators, demodulators, and processors for use by system operators for signal acquisition, processing, and manipulation to create an analog channel lineup for further transmission. Further, it provides hybrid-fiber coax distribution products comprising broadband amplifiers, directional taps, splitters, and wall outlets for coax distribution and fiber optic transmitters, receivers, and couplers. Additionally, the company offers data products to deliver data, video, and voice-over-coaxial in hospitality, multiple dwelling unit, and college campus locations; and test instruments, contract manufacturing and technical services, reception products, and miscellaneous products and services. It serves television broadcasters, cable system operators, and lodging/hospitality video and high-speed Internet system operators, as well as commercial/institutional/enterprise system operators, including educational campus environments, correctional facilities, short and long term health service environments, sports stadiums, and airport terminals through its sales force and stocking distributors. Blonder Tongue Laboratories, Inc. was founded in 1950 and is headquartered in Old Bridge, New Jersey.

Details
Name: Blonder Tongue Laboratories, Inc.
BDR
Exchange: AMEX
Founded: 1950
$9,038,692
9,595,215
Website: http://www.blondertongue.com
Address: Blonder Tongue Laboratories, Inc.
One Jake Brown Road,
Old Bridge,
New Jersey, 08857,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX BDR Common Stock NYSE MKT LLC US USD 14. Dec 1995
Number of employees
Current staff
Staff numbers
117
Blonder Tongue Laboratories employees.
Industry
Communications Equipment
Tech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/18 23:36
End of day share price update: 2019/07/18 00:00
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.